A phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's disease.
A Phase 2a multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with moderate to severe crohn's disease involving Risankizumab, ABBV-382, and Litikizumab.
A Phase 3b, randomized, multicenter, controlled study of Mirikizumab and placebo or Mirikizumab concomitantly administered with Tirzepatide in adult participants with moderately to severely active Crohn's disease and obesity or overweight.